New data from an extension period of a phase 3 study of Samsung Bioepis’ SB2 (Renflexis) in patients with moderate to severe rheumatoid arthritis found that there was no clinically meaningful difference in safety, efficacy, or immunogenicity in patients who were switched from reference infliximab to the biosimilar compared with patients who continued treatment with either the reference or the biosimilar without switching.
New data from an extension period of a phase 3 study of Samsung Bioepis’ SB2 (Renflexis) in patients with moderate to severe rheumatoid arthritis (RA) found that there was no clinically meaningful difference in safety, efficacy, or immunogenicity in patients who were switched from reference infliximab to the biosimilar compared with patients who continued treatment with either the reference or the biosimilar without switching. Additionally, patients who received the biosimilar alone, and were not switched, maintained long-term efficacy, safety, and immunogenicity that was comparable with patients who received the reference product alone.
The new data present clinical efficacy and safety results of SB2 in patients with RA for up to 78 weeks (previous reports were up to week 54). The objective of this extension was to investigate whether patients being treated for RA with reference infliximab could be switched to SB2 without major concerns, and whether comparable efficacy, safety, and immunogenicity were maintained after the switch (compared with continued treatment with either reference infliximab or SB2 only).
Patients with RA who had participated in the original 54-week, double-blind period and who were willing to participate in the extension (n = 396) were randomized to either transition to SB2 from reference infliximab (n = 94) or to continue treatment with reference infliximab (n = 101) or SB2 (n = 201), up to week 70. The final follow-up occurred at week 78.
Treatment efficacy among the 3 arms was comparable at week 78 in terms of the American College of Rheumatology (ACR) responses of 20%, 50%, and 70% improvement:
The percentage of patients achieving good European League Against Rheumatism (EULAR) responses at week 78 were as follows:
The percentage of patients in each arm who developed new ADAs to their assigned treatment were as follows:
The study’s authors concluded that the clinical profile of SB2, administered either in the long term or when switched from the reference infliximab, is comparable with that of the reference. “Our data showing that switching from originator to biosimilar is safe and effective are corroborated by the recent observations in the NOR-SWITCH and DANBIO [studies],” said the authors.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.